Vijayakanth Pagadala
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$13.7MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $13.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2025 | NIH | SBIR Phase II Development of dekaparin to replace animal-sourced heparin | $991K | GLYCAN THERAPEUTICS CORPORATION |
| Aug 1, 2025 | NIH | SBIR Phase II Development of anticoagulant sulfated glycans | $1.1M | GLYCAN THERAPEUTICS CORPORATION |
| Sep 19, 2024 | NIH | SBIR Phase II Development of anticoagulant sulfated glycans | $1.1M | GLYCAN THERAPEUTICS CORPORATION |
| Sep 17, 2024 | NIH | SBIR Phase II Development of dekaparin to replace animal-sourced heparin | $747K | GLYCAN THERAPEUTICS CORPORATION |
| Aug 16, 2023 | NIH | SBIR Phase I Development of anticoagulant sulfated glycans | $356K | GLYCAN THERAPEUTICS CORPORATION |
| Sep 15, 2021 | NIH | SBIR Phase I Quantitative analysis of heparan sulfate using 13C-labeled standards | $300K | GLYCAN THERAPEUTICS CORPORATION |
| Sep 2, 2021 | NIH | SBIR Phase II Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | $273K | GLYCAN THERAPEUTICS CORPORATION |
| Feb 15, 2021 | NIH | SBIR Phase II Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | $1.2M | GLYCAN THERAPEUTICS CORPORATION |
| Jun 19, 2020 | NIH | SBIR Phase II Development of a New Carbohydrate-based Anticoagulant Drug | $1.2M | GLYCAN THERAPEUTICS CORPORATION |
| Mar 1, 2020 | NIH | SBIR Phase II Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | $2.7M | GLYCAN THERAPEUTICS CORPORATION |
| Jul 22, 2019 | NIH | SBIR Phase II Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | $537K | GLYCAN THERAPEUTICS CORPORATION |
| Jul 4, 2019 | NIH | SBIR Phase II Development of a New Carbohydrate-based Anticoagulant Drug | $2.5M | GLYCAN THERAPEUTICS CORPORATION |
| — | NIH | SBIR Phase II CHEMOENZYMATIC SYNTHESIS OF HEPARAN SULFATE OLIGOSACCHARIDES | $694K | GLYCAN THERAPEUTICS CORPORATION |
Peer ranks
Federal funding#26
Awards as PI#72
Patents#273
Companies
- GLYCAN THERAPEUTICS CORPORATIONLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.